News

Researchers at the USDA’s Agricultural Research Service and US Biologic, Inc., have developed an oral solution to an antibiotic alternative that fights against poultry coccidiosis, which costs the poultry industry $3.5B in annual losses worldwide. Full article

“US Biologic envisions a world where everyone has equitable access to lifesaving technologies,” stated Mason Kauffman, CEO of US Biologic. “Our mission is to reduce disease through predictive analytics and orally delivered vaccines and therapeutics delivered to the home. The SAMS Coalition will help impact policy to rebuild American infrastructure and strategic product stockpiles, and…

The U.S. DHHS Biomedical Advanced Research and Development Authority (BARDA) Division of Research Innovation and Ventures (DRIVe) is partnering with US Biologic Inc. to advance the development of an oral vaccine for the influenza virus. This partnership aligns with the goals of BARDA DRIVe’s Beyond the Needle program: to make vaccines and therapeutics easier to administer and…

A Memphis-based biotech company announced in early August a partnership with a federal agency to work on a temperature stable, oral vaccine against two strains of the influenza virus. US Biologic, known for its proprietary oral-delivery platform OrisBio, produces oral vaccines and therapeutics, which are currently being used in animals to prevent zoonotic diseases. The company…